New long-term data from the CROWN study offer hope to people with ALK-positive non-small cell lung cancer. After seven years of follow-up, lorlatinib appears to provide durable disease control in a proportion of patients.
For the ALK+ community this is important news. ALK+ lung cancer is a form of lung cancer in which a change in the ALK gene drives the growth of cancer cells. Thanks to targeted treatments such as ALK inhibitors, this specific alteration can be addressed increasingly well.
What did the CROWN study investigate?
In the CROWN study, lorlatinib was compared with crizotinib as a first-line treatment in people with advanced ALK+ lung cancer. Both agents are ALK inhibitors, but lorlatinib is a newer generation of treatment.
An important endpoint was progression-free survival: the period during which the disease does not measurably worsen.
What makes the results notable?
After seven years, median progression-free survival had still not been reached among patients receiving lorlatinib. That means more than half of this group had not yet experienced disease progression at that point.
Disease control in the brain was also reported to have remained notably strong. That is relevant, because ALK+ lung cancer relatively often spreads to the brain.
These results show how substantial the progress in ALK+ lung cancer has been over recent years. Where lung cancer was once often regarded as a single disease, doctors today can treat increasingly precisely on the basis of molecular features such as ALK.
What does this mean for patients?
The results are hopeful, but they do not mean every patient will respond in the same way. Treatment choices remain personal and depend on factors including previous treatments, side effects, general health and the presence of brain metastases.
Lorlatinib can also cause side effects, such as changes in cholesterol levels, weight gain, fluid retention, or cognitive and mood-related complaints. Careful follow-up by the treating team therefore remains important.
A step forward
The 7-year CROWN data represent an important milestone for people with ALK+ lung cancer. They show that durable disease control is possible for a proportion of patients.
For ALK+ Belgium, these results underline how important research, access to targeted therapies and clear patient information remain.
Every new update brings more knowledge. And with more knowledge comes more hope.
This article is intended as general information and does not replace medical advice. Always discuss questions about treatment, side effects or clinical studies with your doctor or care team.